The study of Gluquamin anti-aggregant properties for experimental renal failure
DOI:
https://doi.org/10.24959/ubphj.18.184Keywords:
gluquamin, quercetin, renal failure, glomerulonephritis, platelet aggregationAbstract
Topicality. Chronic kidney disease (CKD) is one of the most common urinary system diseases, which leads not only to inevitable renal failure, but also to kidneys hemodynamics worsening and platelet activity increase. Therefore, when searching for a new agents for CKD treatment, it is advisable to study their anti-aggregant properties.
Aim. Experimental study of Gluquamin drug effect on the platelet aggregation in con-ditions of renal failure development to justify its use in CKD therapy.
Materials and Methods. Heiman’s active nephritis was used as a model of renal failure. The stimulated platelet aggregation was determined in rats using turbidimetric method with an aggregometer.
Results and Discussion. Under the influence of Gluquamin on the 120th day of study there was a significant decrease of the ADP-induced platelet aggregation relatively to untreat-ed animals, which indicates a decrease of the blood level of activated platelet forms. Also in rats there was a decrease of the collagen-stimulated aggregation, which indicates a decrease of the sensitivity of platelets to the components of the vascular wall and basal membranes. At the same time according to Gluquamin influence degree was superior to the activity of compara-tive drugs quercetin and lespephril.
Conclusions. Under the conditions of renal failure development on the background of glomerulonephritis in rats Gluquamin has a pronounced anti-aggregant effect, normalizes he-modynamics, rheological properties of blood and is a promising drug in CKD therapy.
References
Skvortcov, V. V., Tumarenko, A. V. (2017). Klinicheskaia nefrologiia : kratkii kurs. Sankt-Peterburg: SpetcLit, 199.
Pyroh, L. A., Ivanova, D. D. (eds). (2014). Nefrolohiia: natsionalnyi pidruchnyk. Donetsk: Zaslavskyi, 292.
Shebeko, S. K. (2017). Comparative experimental study of nephroprotective properties of glucosamine derivatives in combination with quercetin.
Ukraïns’kij bìofarmacevtičnij žurnal, 5(52), 40–44. https://doi.org/10.24959/ubphj.17.139
Shebeko, S. K., Zupanets, I. A., Propisnova, V. V., & Shalamay, A. S. (2018). Experimental study of Gluquamine efficacy in the case of tubular kidney
damage. Ukraïns’kij bìofarmacevtičnij žurnal, 2(55), 56–60. https://doi.org/10.24959/ubphj.18.170
Shebeko, S. K., Zupanets, I. A., Shalamai, A. S. (2017). Farmakolohiia ta likarska toksykolohiia, 6 (56), 66–71.
Shebeko, S. K., Zupanets, I. A., & Shalamay, A. S. (2018). Study of glucuamine specific action under conditions of diabetic nephropathy in the experiment. Ukraïns’kij bìofarmacevtičnij žurnal, 1(54), 25–30. https://doi.org/10.24959/ubphj.18.155
Guide for the care and use of laboratory animals, 8th edition. (2011). Washington : The National Academies Press, 246.
European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe (1986). Strasbourg, 52.
Shtryhol, S. Yu., Lisovyi, V. M., Zupanets, I. A. (2009). Metody eksperymentalnoho modeliuvannia urazhennia nyrok dlia farmakolohichnykh doslidzhen:
metodychni rekomendatsii. Kharkiv: NFaU, 48.
Shebeko, S. K. (2017). Liky Ukrainy plius, 4 (33), 26–29.
Stephanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennyh sredstv. Kiev: Avitcenna, 528.
Barkagan, Z. S., Momot, A. P. (2008). Diagnostika i kontroliruemaia terapiia narushenii gemostaza. Moscow: Niudiamed-AO, 292.
Kozlovskii, V. I., Kovtun, O. M., Serouhova, O. P., Detkovskaia, I. N., Kozlovskii, I. V. (2013). Vestnik VGMU, 12 (4), 79–91.
Truhacheva, N. V. (2012). Matematicheskaia statistika v mediko–biologicheskih issledovaniiah s primeneniem paketa Statistica. Moscow: GEOTAR–Media, 379.
Engin, A. B., Engin, A. (eds). (2013). Endothelium: molecular aspects of metabolic disorders. CRC Press, 468.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
